AstraZeneca’s Soriot Open to Buying Immune-Therapy Company

AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body’s immune response, Chief Executive Officer Pascal Soriot said.

“If at some point we conclude we need to make an acquisition, we certainly would consider it, there’s no question about it,” Soriot said in an interview, in response to a question about whether AstraZeneca would consider buying a CAR T asset such as Juno Therapeutics Inc. Juno went public last year and is valued at about $4.8 billion.